China Biotech Weekly #13: The BIOSECURE Countdown — 9 Months Until the BCC List Reshapes China Pharma Partnerships

This Week's Top Takeaway

The BIOSECURE Act's BCC list deadline is December 2026 — 9 months away — and the three designation categories create different risk profiles that most compliance teams are conflating. Category A (1260H entities) is near-certain. Category B (OMB interagency) is where WuXi's fate will be decided. Category C (subsidiaries) is the sleeper risk that could cascade through complex Chinese holding structures. Your CDMO transition plan should be calibrated to categories, not headlines.

BIOSECURE Watch

Status: 🟡 New Development

The OMB interagency review process is underway, with the December 2026 deadline for BCC list publication approaching. Three developments this week:

1. SEC risk factor disclosures continue to accelerate. Two additional mid-cap biotechs filed BIOSECURE as a material risk factor in their 10-K filings this week, bringing the running total to approximately 15 public companies. The disclosure language continues to converge around a standard template — suggesting outside counsel are aligning on recommended risk factor text for companies with Chinese CDMO exposure. 2. WuXi AppTec (药明康德) released its 2025 annual report showing continued revenue growth from US clients, while simultaneously accelerating its corporate restructuring. The company's planned IPO of WuXi XDC (its ADC-focused subsidiary) is being interpreted by compliance attorneys as a preemptive move to isolate potentially designated entities from commercially critical operations. 3. Congressional activity remains elevated but no new legislation has been introduced. The focus has shifted from statutory language to OMB implementation — specifically, how broadly the Category B interagency process will be interpreted and whether the "biotechnology" definition will be construed narrowly (genomics-focused, as in the 1260H list precedent) or broadly (encompassing CDMO/CRO services). Action item: If your organization uses WuXi services, the key question is not "will WuXi be designated?" but "which WuXi entity do you contract with, and what's its relationship to any potentially designated parent?" Category C subsidiary analysis is where compliance teams should be spending their time.

CDE Filing Watch

Notable filings from China's Center for Drug Evaluation (国家药品监督管理局药品审评中心) this week:

Akeso (康方生物) received CDE acceptance for a supplemental NDA for ivonescimab (PD-1/VEGF bispecific) in first-line NSCLC. This is the competitive asset that prompted BMS's $11.1B BioNTech deal for BNT-327. BD teams tracking the PD-1/VEGF bispecific space: Akeso is now 6-12 months ahead of Innovent's competing program in the Chinese regulatory pathway.

Kelun-Biotech (科伦博泰) filed a new IND for an undisclosed ADC target. Kelun has emerged as one of China's most prolific ADC platforms, with its Merck partnership ($9.4B total across multiple ADC candidates) validating its linker-payload technology. This new filing suggests pipeline depth beyond the Merck-partnered assets.

3SBio (三生制药) submitted a Phase III protocol amendment for its bispecific antibody program partnered with Pfizer. The amendment aligns the China development timeline with Pfizer's global registration strategy — consistent with the trend of synchronized CDE-FDA development programs for out-licensed Chinese assets.

Takeaways for BD Teams

Pre-clinical China deals need different comp sets than clinical-stage deals. The AZ-CSPC 0.5% upfront ratio and the Pfizer-3SBio 26% ratio are both rational — for completely different risk profiles. Stop using headline biobucks for benchmarking. Structure your comps by stage, modality, and competitive position.

BIOSECURE Category C is the compliance sleeper. Most teams are tracking Category A (BGI — obvious) and Category B (WuXi — uncertain). But Category C — subsidiaries, parents, and successors of designated entities — could cascade through complex Chinese holding structures in ways that aren't obvious from English-language corporate filings. Map your exposure through Chinese registries, not SEC filings.

The CDE-FDA synchronization trend is accelerating. Three of this week's notable CDE filings involve coordinated global development strategies. This means the window between a Chinese IND filing and a potential US licensing opportunity is compressing. BD teams that monitor CDE filings weekly have a 6-12 month intelligence advantage over those who wait for English-language deal announcements.

Don't sleep on Chinese small molecules. The AZ-CSPC deal proves the opportunity extends beyond bispecifics and ADCs. CSPC's cardiovascular chemistry, Hengrui's (恒瑞医药) metabolic pipeline, and Hansoh Pharma's (翰森制药) CNS portfolio all represent untapped licensing opportunities for companies focused exclusively on biologics.

China Biotech Weekly is published every Thursday. For questions, tips, or deal intelligence, reach out at antony@chinabiointel.com. — Antony Tan